-1366x0.jpg)
ESHRE – The World’s Leading Annual Event in Reproductive Medicine
ESHRE (European Society of Human Reproduction and Embryology) is the largest international conference in the field of reproductive medicine and embryology. Held annually in July by the European Society of Human Reproduction and Embryology, the event brings together thousands of experts, researchers, physicians, and global health organizations to share knowledge, research findings, and the latest trends in the treatment of infertility.
In 2025, the ESHRE conference will take place at the Paris Convention Centre – Porte de Versailles, one of the most modern and largest venues in Europe, from June 29 to July 2, 2025. This is a valuable opportunity for healthcare professionals to update their knowledge, expand professional networks, and jointly advance the field of reproductive medicine – a domain deeply rooted in human compassion and care.
GENTIS Research on Segmental Mosaic Embryos Selected for Oral Presentation
GENTIS is honored to have its research project titled: “Decoding the clinical fate of segmental mosaic embryos: key predictors of implantation and pregnancy success”
(selected Vietnamese title: "Giải mã kết cục lâm sàng chuyển phôi khảm cấu trúc một phần: các yếu tố chủ đạo dự đoán sự thành công chuyển phôi và mang thai IVF")
chosen by the ESHRE Scientific Committee for oral presentation – the highest and most prestigious form of presentation at the conference.
The Study Focuses on Segmental Mosaic Embryos – A Promising Yet Controversial Path in IVF
The research centers on segmental mosaic embryos – a type of embryo containing both normal and abnormal cells due to errors in mitotic cell division. The use of such embryos in IVF has long been controversial, yet it presents a promising option when no euploid embryos (chromosomally normal) are available.
The main objective of the study is to evaluate the implantation potential, pregnancy outcomes, and live birth rates of segmental mosaic embryos, thereby identifying key predictors of clinical success and proposing safer embryo selection criteria for IVF practice.
Data and Research Methods
This is a retrospective study, analyzing data from 3,790 mosaic embryos recorded in the International Registry of Mosaic Embryo Transfers (IRMET) between 2017 and 2024. The methodology includes:
- Embryo classification:
- Segmental mosaic embryos: 1,567
- Whole-chromosome mosaic embryos: 1,723
- Euploid embryos: 19,258
- Embryo characteristics:
- Degree of mosaicism (percentage of abnormal cells)
- Type of abnormality (segmental deletion or duplication)
- Size of the affected chromosomal segment
- Embryo morphology (Inner Cell Mass – ICM, and Trophectoderm – TE)
- Timing of biopsy (Day 4–6)
- Clinical outcomes analyzed:
- Implantation rate
- Clinical pregnancy rate
- Live birth rate
- Miscarriage rate
- Statistical methods:
- Logistic regression analysis
- Chi-square tests
- Standardized sequencing platform for consistent results
Key Findings
The study revealed several important factors that directly influence the clinical success of mosaic embryo transfer, including:
- The ongoing pregnancy rate (OPR) for segmental mosaic embryos was 45.5%, higher than whole-chromosome mosaics (34.3%) but lower than euploid embryos (50%).
- Higher levels of mosaicism significantly reduced OPR:
- 50% success at 20% mosaicism
- 45% at 30–40%
- Only 27% at 60%
- Embryos with small deletions, particularly on short chromosomal arms, showed higher success rates compared to large deletions or duplications.
- Timing of biopsy strongly affected outcomes: biopsies done on Day 4–5 yielded better results than those on Days 5 or 6.
- Embryos with high-quality morphology (ICM and TE) achieved superior clinical outcomes.
These findings emphasize that embryo selection for mosaic transfer should be based on multiple integrated criteria, rather than solely relying on classification from PGT-A (Preimplantation Genetic Testing for Aneuploidy).
Significance and Contributions of the Study
This research represents the first large-scale dataset on segmental mosaic embryos, with contributions from 20 IVF centers worldwide. Its practical impact includes:
- Enhancing clinical understanding of mosaic embryo behavior
- Supporting more informed and optimized embryo selection
- Contributing to the standardization of PGT-A reporting criteria, ultimately improving the safety and effectiveness of mosaic embryo transfer
This study also marks an important milestone for GENTIS, showcasing its commitment to rigorous scientific research, alignment with global trends, and its mission to accompany patients on their journey through infertility treatment.
Being selected for an oral presentation at ESHRE 2025 is a proud achievement, not only for GENTIS but for Vietnam’s entire reproductive medicine community. We firmly believe that our continued efforts in research and innovation will enhance IVF success rates and expand the possibility of parenthood for millions of families around the world.
